Bispecific canine antibodies for treating atopic dermatitis
Bispecific antibodies targeting IL-31, IL-22, and IL-4Rα receptors in dogs with atopic dermatitis simultaneously address inflammation, skin barrier improvement, and pruritus, overcoming limitations of current therapies.
JP7875803B2Active Publication Date: 2026-06-18INTERVET INT BV
View PDF 15 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- INTERVET INT BV
- Filing Date
- 2020-12-18
- Publication Date
- 2026-06-18
AI Technical Summary
Technical Problem
Current therapies for atopic dermatitis in dogs fail to simultaneously address skin inflammation, improve skin barrier function, and provide rapid antipruritic action.
Method used
Development of bispecific antibodies comprising canine antipruritic, antiproliferative, and anti-inflammatory antibodies, which target IL-31, IL-22, and IL-4Rα receptors to regulate IL-4, IL-31, and IL-22 signaling, thereby reducing pruritus, inflammation, and improving skin barrier function.
Benefits of technology
The bispecific antibodies effectively reduce skin inflammation, improve skin barrier function, and provide rapid antipruritic effects in dogs with atopic dermatitis.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007875803000013 
Figure 0007875803000014 
Figure 0007875803000015
Abstract
The present invention provides a composition for treating canine atopic dermatitis, comprising a caninized anti-proliferative antibody, a caninized anti-pruritic antibody, and a caninized anti-inflammatory antibody. The present invention further relates to a bispecific antibody comprising a caninized anti-pruritic antibody and a caninized anti-proliferative antibody, or a bispecific antibody comprising a caninized anti-pruritic antibody and a caninized anti-inflammatory antibody.
Need to check novelty before this filing date? Find Prior Art